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Abstract
Introduction: Many supposed low-risk intensive care unit (ICU) admissions develop acute organ failure (AOF).
Identifying patients at high risk of developing AOF and targeting them with preventative strategies may be
effective. Our study question was: in a population of ICU patients receiving positive pressure respiratory support
(invasive or non-invasive) in the absence of non-respiratory AOF, what is the 14-day incidence of, risk factors for
and time to acute organ failure?
Methods: In an international prospective cohort study, patients receiving positive pressure respiratory support
(invasive or non-invasive) in the absence of non-respiratory AOF were enrolled and followed for 14 days. The
primary outcome measure was the incidence of any AOF (defined as SOFA 3 to 4) during follow-up.
Results: A total of 123 of 766 screened patients (16.1%) were enrolled. Data are reported for 121 patients. In total,
45 out of 121 patients (37.2%) developed AOF. Mortality rates were higher in those with AOF: 17.8% versus 4.0%
OR 5.11, P = 0.019) for ICU mortality; and 28.9% versus 11.8% (OR 2.80, P = 0.019) for hospital mortality. Median ICU
length of stay was also longer in those with AOF (11 versus 3.0 days; P < 0.0001). Hypoxemic respiratory failure
(P = 0.001) and cardiovascular dysfunction (that is, SOFA 1 to 2; P = 0.03) were associated with AOF. The median
time to first AOF was two days.
Conclusions: Patients receiving positive (invasive or non-invasive) pressure respiratory support in the absence of
non-respiratory AOF are commonly admitted to ICU; AOF is frequent in these patients. Organ failure developed
within a short period after admission. Hypoxemic respiratory failure and cardiovascular dysfunction were strongly
associated with AOF.
Introduction
Patients with severe infections and early sepsis can
develop acute organ failure (AOF) [1-3]. Risk of death
correlates with the severity and duration of AOF [1].
Except for antibiotics and source control, the current
management of sepsis is largely supportive as many
potential treatments have failed in randomized trials
[4-7]. A different approach to managing AOF is to
identify high-risk patients and target them with preven-
tative strategies. For example, Rivers et al demonstrated
a reduction in mortality when patients with severe sepsis
were treated early [8]. However, these patients already
suffered AOF. Another example is statin therapy,
recently highlighted as a possible efficacious preventative
strategy [9,10].
We want to explore whether, in patients with no non-
respiratory organ failure who receive positive pressure
respiratory support, an opportunity exists to introduce
preventative treatments before the onset of multiple
organ failure. This approach is based on the premise that
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mechanical ventilation may be associated with ventilator-
associated pneumonia, acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS), and also increases
the risk of developing other non-respiratory organ
failures [11-15].
This international cohort study had three aims. First, to
establish whether the target population (at-risk patients
receiving positive pressure respiratory support in the
absence of non-respiratory organ failure) are admitted to
participating ICUs frequently enough to make a rando-
mized controlled trial (RCT) feasible; second, to establish
the incidence of AOF and identify baseline risk factors;
and third, to confirm the presence of a treatment window
sufficiently long to allow the testing of preventative
interventions.
We hypothesized that many ICU patients receiving posi-
tive pressure ventilatory support develop AOF within
14 days, and that there would be identifiable risk factors
for this subgroup. Based on this hypothesis our a priori
stated study question was: in a population of ICU patients
who receive positive pressure respiratory support (invasive
or non-invasive) in the absence of non-respiratory organ
failure, what is the 14-day incidence of and baseline risk
factors for AOF (defined by a sequential organ failure
assessment (SOFA) score ≥ 3) [16]?
Materials and methods
Study design and setting
We performed an international prospective cohort study.
Eleven adult ICUs in three countries participated: nine in
the United Kingdom and one each in Canada and
Australia. Nine were based in universities and two in
general hospitals.
Participants
Screening took place between May 2009 and March
2010; each centre screened all admissions for an uninter-
rupted four-week period. All admissions to ICUs were
screened during the first 24 hours after intensive care
unit/high dependency unit (ICU/HDU) admission. All
adults receiving positive pressure respiratory support
(invasive or non-invasive) for at least one hour were eligi-
ble for inclusion. Positive pressure support included any
combination of positive end-expiratory support (PEEP)
and positive pressure inspiratory support.
Patients were excluded if they, at the time of meeting
the inclusion criteria, had any non-respiratory AOF
(defined by a SOFA score ≥ 3 in that organ system) [16].
Moribund patients or those for whom care was limited
were also excluded. We excluded elective surgical
patients if they were extubated and ready to return to the
ward on the morning after admission. To ensure only
patients free of non-respiratory AOF were enrolled, we
excluded those who, at screening, had any missing data
related to the inclusion and/or exclusion criteria.
Data collection and follow-up
Comprehensive baseline demographic, severity of illness
and admission data were entered into a custom-
designed database (Microsoft Access™, Microsoft Corp,
Seattle, WA, USA). Microbiological results for samples
obtained within 48 hours prior to ICU admission were
recorded. Daily organ function, physiological, laboratory
and treatment data were recorded for up to 14 days.
Location on day 28 and vital status at ICU and hospital
discharge were recorded.
Primary outcome
The primary outcome was the incidence of AOF during
the follow-up period. AOF, defined as a SOFA ≥ 3, was
a composite of any non-respiratory organ failure, or the
onset of respiratory failure in only those without respira-
tory failure (SOFAresp < 3) at inclusion [16]. The neuro-
logical component was not considered in the analysis.
Sample size calculations and statistical methods
Data for the screened cohort are presented using values
recorded at the time of screening. Baseline data for the
eligible cohort are presented using values recorded at the
end of the 24-hour screening window. The distributions
of all variables were tested for normality; parametric tests
were used for with a normal distribution and non-para-
metric tests for those without. Data are presented as
means (standard deviation, SD), median (interquartile
range, IQR) and number (percentage, %). Baseline differ-
ences between outcome groups were compared using
standard tests for continuous and binary variables. We
report the number and/or proportion of patients with
missing values. Stata/SE Version 11.0 (StataCorp LP,
College Station, TX, USA) was used for all analyses.
Given the exploratory nature we did not perform an a
priori sample size calculation. A P ≤ 0.05 was considered
statistically significant for two-sided tests.
Variables associated with AOF (P < 0.20) or those
potentially associated on clinical or biological grounds
were included in regression models. Single and multiple
variable models used combinations of c2 tests and logis-
tic regression techniques that treated AOF as dependent
variable.
The study’s exploratory nature required non-parsimo-
nious multivariable regression models to identify vari-
ables for further exploration in future studies. Models
were constructed using automatic stepwise selection
estimation with likelihood ratio testing (P-value ≤ 0.20)
specified as the test of significance to include or exclude
variables.
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Ethics approval
For UK sites: the Guy’s and St. Thomas’ NHS Foundation
Trust Multi-Centre Research Ethics Committee (09/
H0802/23); for Australia: the Princess Alexandra Hospital
Human Research Ethics Committee (2009/029); and for
Canada: the University Health Network Research Ethics
Board (09-0811-AE). Due to the observational design all
three research ethics committees (RECs) waived the need
for consent.
Results
Admission frequency and characteristics of target
population
Frequency
A total of 766 patients were screened (baseline data pre-
sented in Table S1 in Additional file 1); 123 (16.1%) met
the inclusion criteria and were eligible for follow-up
(Figure 1). Overall mean (SD) age was 57.5 (18) years and
the acute physiology and chronic health evaluation
(APACHE II) score 14.8 (7.2) for screened patients.
Median (IQR) SOFA total score was 4 (6).
No differences in APACHE II (P = 0.196) and age (P =
0.24) were observed between eligible and non-eligible
patients. In non-eligible patients, cardiovascular failure
was the most common cause for presentation (n = 290/
643, 45.1%). Other organ failures present at screening
were renal (n = 118/643, 18.34%), haematological (n = 36/
643, 5.6%) and hepatic (n = 24/643, 3.7%).
Admission characteristics
Two patients met the eligibility criteria but were dis-
charged soon after enrolment; follow-up data are therefore
available for 121 patients (Table 1). Mean (SD) age and
APACHE II (n = 120) were 56.0 (19.1) and 13.8 (6.3),
respectively. Most patients had respiratory organ dysfunc-
tion or failure at the outset. The median (IQR) respiratory
SOFA score was 2 (3). Sixty-three patients (51.2%) had
respiratory failure at inclusion. Total SOFA scores includ-
ing and excluding the respiratory components were 4 (4)
and 1 (2), respectively. Additional data not presented here
are included in Tables S2 and S4 in Additional file 1.
Incidence of and risk factors for acute organ failure
Incidence
In total, 45 out of 121 patients (37.2%; 95% confidence
index (CI) 28.6 to 46.4%) developed AOF. Some 35
patients developed non-respiratory AOF, while 22 out of
60 patients (36.7%) with respiratory SOFA scores < 3
developed frank respiratory failure.
Outcomes associated with acute organ failure
The overall ICU and hospital mortalities were 9.2% and
18.2%, respectively (Table 2). Median (IQR) length of
ICU stay (iLOS) was 4.0 (8.0) days. Mortality rates were
significantly higher in those who developed AOF: 17.8%
versus 4.0% odds ratio (OR) 5.11, 95% CI 1.28 to 20.44,
P = 0.019) for ICU mortality; and 28.9% versus 11.8%
(OR 2.80, 95% CI 1.06 to 7.40, P = 0.019) for hospital
mortality. iLOS also differed significantly: those who
developed AOF had a median (IQR) iLOS of 11 (17.5)
days versus 3.0 (4.0) for those who did not (P < 0.0001).
Baseline differences
There were no between-group differences in age, gender or
the presence of comorbidities (P > 0.05), but APACHE II
scores were significantly lower in those who did not
develop AOF (15.8 versus 12.5, P = 0.005). Whilst admis-
sion with an infection was more likely in those who devel-
oped AOF (P = 0.041), the presence of pneumonia (P =
0.67) or positive microbiological results (P = 0.606) were
not.
At baseline, differences were observed in individual
organ system SOFA scores (median, IQR) between those
patients that developed AOF and those that did not.
Respiratory SOFA was 3 (3) versus 2 (3), P = 0.019; renal:
0 (1) versus 0 (0), P = 0.048; cardiovascular: 1 (3) versus 1
(1), P = 0.002; and hepatic: 0 (1) versus 0 (0), P = 0.016.
Furthermore, there were also significant differences in
total SOFA score (including and excluding the respiratory
component) between the two outcome groups (P < 0.0001
for both).
Univariate analysis
Variables significantly associated with the development
of AOF (OR, 95% CI, P-value) included (Table 3):
APACHE II score (1.09 per APACHE II point, 1.02 to
1.17, 0.01); admission ratio of partial pressure of arter-
ial oxygen to the fraction of inspired oxygen (PaO2/
FiO2 ratio) (0.80 per 1 unit change, 0.58 to 1.00, 0.04);
receiving positive end-expiratory pressure (PEEP) and
positive pressure inspiratory support (8.95, 1.12 to
71.42, 0.04); admission with an infection (2.42, 1.02 to
5.73, 0.04); the presence of cardiovascular dysfunction
(2.80, 1.55 to 5.05, 0.03); renal dysfunction (2.21, 1.10
to 4.45, 0.03), and/or hepatic dysfunction (2.67, 1.11 to
6.39, 0.03).
Multivariable regression analysis
In non-parsimonious multivariable analysis (Table 3) the
presence of type 1 respiratory failure (that is, failure of
oxygenation; adjusted OR 5.63, 95% CI 1.95 to 16.26, P
= 0.001) and the presence of cardiovascular dysfunction
(that is, SOFA 1 to 2; adjusted OR 2.10, 95% CI 1.07 to
4.12, P = 0.03) were associated with AOF. Receiving a
statin on the first day of ICU was associated with a
trend towards lower risk of AOF (OR 0.18, 95% CI 0.03
to 1.13, P = 0.07). Conversely, prior statin therapy (1.16,
0.99 to 1.35, 0.064), the presence of renal dysfunction
(2.32, 0.93 to 5.79, 0.07), and APACHE II (1.08 per
point, 1.00 to 1.17, 0.06) were associated with a trend
towards higher risk.
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Time to acute organ failure
The median time to develop AOF was two days (Figure
2). The median time to non-respiratory AOF was one
day, contrasting the median six days for respiratory
failure to develop in those with a respiratory SOFA
score < 3 on admission. The median time to cardiovas-
cular failure was 1.0 day, followed by 1.5 days for hae-
matological and 2.0 days for renal failure (Figure 3).
Total number of admissions during 
screening period: 
n=766 
Died in ICU: 
n=8 (17.8%) 
Died in hospital: 
n=13 (28.9%) 
Total number of patients screened: 
n=766 (100%) 
Number meeting selection criteria: 
n=123 (16.1%) 
Number of patients followed up: 
n=121 
Number who developed acute 
organ failure: 
n=45 (37.2%) 
Number excluded: 
n=643 (83.9%) 
Number of patients not followed 
up: n=2 
Number who did not develop acute 
organ failure: 
n=76 (62.8%) 
Died in ICU: 
n=3 (4.0%) 
Died in hospital: 
n=9 (11.8%) 
Median (IQR) length of ICU stay: 
11 (17.5) days 
Median (IQR)  length of ICU stay: 
3 (4) days 
Figure 1 Flow diagram of study patients and outcomes.
Terblanche et al. Critical Care 2012, 16:R61
http://ccforum.com/content/16/2/R61
Page 4 of 10
In those who developed AOF, cardiovascular (n = 26/
45, 57.8%) and renal (n = 14/45, 31.1%) failure were most
common (Table S3 in Additional file 1). Interestingly,
while few develop haematological or hepatic failure,
48.9% and 40.0%, respectively, developed dysfunction of
these systems.
Discussion
Key results
In this international prospective cohort study, nearly one
in six (16.1%) admissions met the selection criteria, sup-
porting the supposition that a less sick population is
available for enrolment in future trials. The results
Table 1 Baseline data for eligible patients.
Cohort, n = 1215 Progressed to AOF,
n = 45 (37.2%)
No progression to AOF,
n = 76 (62.8%)
P-value
Demographic data1
Age 56.0 (19.1) 58.1 (19.8) 54.7 (18.7) 0.432
Female gender 40 (33.1) 15 (33.3) 25 (32.9) 1.0
APACHE II 13.8 (6.3), n = 120 15.8 (5.6) 12.5 (6.2), n = 75 0.005
Chronic comorbidities 53 (43.8) 22 (49.0) 31 (40.8) 0.45
Current smoker 23 (19.0), n = 83 12 (26.7), n = 34 11 (14.5), n = 36 0.19
Previous statin therapy 26 (21.5), n = 105 8 (17.8), n = 36 18 (23.7), n = 69 0.23
Admission characteristics2
Reason for admission:
Respiratory infection 21 (17.4) 10 (22.2) 11 (14.5) 0.277
COPD/Asthma 8 (6.6) 2 (4.4) 6 (7.9) 0.709
Respiratory 31 (25.6) 8 (17.8) 23 (30.3) 0.128
Sepsis & septic shock 7 (5.8) 5 (11.1) 2 (2.6) 0.100
Shock (CVS) 8 (6.6) 5 (11.1) 3 (4.0) 0.146
CVS (other) 4 (3.3) 2 (4.4) 2 (2.6) 0.628
Trauma 17 (14.1) 7 (15.6) 10 (13.2) 0.714
Neurological 4 (3.3) 0 (0.0) 4 (5.3) 0.296
Drug overdose 2 (1.7) 0 (0.0) 2 (2.6) 0.529
Gastrointestinal 18 (14.9) 6 (13.3) 12 (15.8) 0.714
Other 1 (0.8) 0 (0.0) 1 (1.3) 1.000
Admission source
OPR/Theatre 43 (35.5) 11 (24.4) 32 (42.1) 0.050
Hospital floor/ward 30 (24.8) 15 (33.3) 15 (19.7) 0.094
ER/A&E 30 (24.8) 10 (22.2) 20 (26.3) 0.614
Other hospital area 5 (4.1) 2 (4.4) 3 (4.0) 1.000
Another hospital 13 (10.7) 7 (15.6) 6 (7.9) 0.188
Other:
Readmission to ICU 12 (9.9) 4 (8.9) 8 (10.5) 1.0
Admitted with any infection 28 (23.1) 15 (33.3) 13 (17.1) 0.041
Admitted with pneumonia3 21 (75.0) 12 (80.0) 9 (69.2) 0.67
Positive microbiological cultures3 42 (40.4) 17 (43.6) 25 (38.5) 0.606
Organ function - SOFA score4
Respiratory 2 (3) 3(3) 2(3) 0.019
Renal 0 (1) 0(1) 0(0) 0.048
Haematological 0(0) 0(1) 0(0) 0.197
Cardiovascular 1(1) 1(3) 1(1) 0.002
Hepatic 0(0) 0(1) 0(0) 0.016
Neurological 2(4) 3(3) 2(3) 0.016
Total SOFA score 4(4) 5(5) 3(3) < 0.0001
Total SOFA score excluding respiratory 1(2) 3(4) 1(2) < 0.0001
1Mean (SD) or total (%) unless otherwise indicated. 2N, (%). 3Further data available in the online addendum. 4Presented as median and interquartile range. 5Two
patients were discharged soon after admission. AOF, acute organ failure; APACHE, acute physiology and chronic health evaluation; COPD, chronic obstructive
pulmonary disease; CVS, cardiovascular; ER/A&E, emergency room/accident & emergency; ICU, intensive care unit; OPR, operating room; SOFA, sequential organ
failure assessment.
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furthermore show that this population is at high risk
(37.2%; 95% CI 28.6 to 46.4%) of AOF, providing key
control event rates on which to base future sample size
calculations. Failure of oxygenation and the presence of
cardiovascular dysfunction were strongly associated with
new AOF. Deterioration is associated with important
clinical outcomes and resource utilization. Compared to
patients who did not develop AOF, those who did were
5.11 (95% CI 1.28 to 20.44) and 2.80 times (95% CI 1.06
to 7.40) more likely to die in ICU and hospital, respec-
tively, and had a median length of stay 4.4 times longer.
The median time to AOF was two days. Cardiovascular
failure developed within one day, while other organs
failed less frequently and over a longer period.
Interpretation
To our knowledge, this is the first study to investigate
specifically and prospectively the risk factors for AOF
in a population defined by a therapeutic intervention.
We believe this cohort of patients to be easily identifi-
able, clinically important and at great risk of develop-
ing AOF. Identifying modifiable risk factors for AOF
and/or testing novel preventative strategies in this
population may therefore yield effective interventions.
Epidemiological data on AOF in early critical illness
are limited and from different populations. Further-
more, these studies use different definitions for AOF
and different scoring systems to assess risks and
severity.
Dremsizov et al studied hospital patients with com-
munity-acquired pneumonia (CAP) and report detailed
incidence and time-course data [17,18]. AOF developed
in 48% of patients and non-pulmonary organ dysfunc-
tion in 39%. Like in our study, renal dysfunction
occurred early, but cardiovascular and haematological
dysfunction occurred later. The frequently used systemic
Table 2 Secondary outcome data.
Cohort, n = 121 Progressed to AOF,
n = 45 (37%)
No progression to AOF,
n = 76 (63%)
P-value
Mortality1
ICU 11 (9.2), n = 120 8 (17.8) 3 (4.0), n = 75 0.019
Hospital 22 (18.2) 13 (28.9) 9 (11.8) 0.019
ICU length of ICU stay, days2 4.0 (8.0), n = 119 11 (17.5), n = 44 3.0 (4.0), n = 75 < 0.0001
1N, (%). 2Median (IQR). AOF, acute organ failure; ICU, intensive care unit; IQR, interquartile range.
Table 3 Risk factors associated with acute organ failure.
Predictor variable Univariate analysis Multivariate analysis (n = 108)
OR1 95% CI P-value OR1 95% CI1 P-value2, 3
Age (years) 1.00 0.99 - 1.03 0.339 0.381
APACHE II 1.09 1.02 - 1.17 (n = 120) 0.008 1.08 1.00 - 1.17 0.064
Female gender 1.02 0.47 - 2.23 0.960 0.668
OPR/Theatre admission 0.44 0.20 - 1.01 0.052 0.324
Admission PaO2/FiO2 ratio 0.80 0.58 - 1.00 (n = 114) 0.038 0.498
Hypoxemic failure 4.56 1.98 - 10.53
(n = 120)
< 0.001 5.63 1.95 - 16.26 0.001
Type 2 (ventilatory) failure 0.11 0.01 - 0.86 (n= 120) 0.035 0.208
Positive end-expiratory pressure support (PEEP) only 0.14 0.02 - 1.12 (n = 116) 0.064 0.411
PEEP and positive pressure inspiratory support 8.95 1.12 - 71.42 (n = 116) 0.039 7.00 0.61 - 79.79 0.117
Endotracheal tube 2.76 1.16 - 6.59 (n = 116) 0.022 0.353
Previous statin therapy 1.10 0.98 - 1.24 0.112 1.16 0.99 - 1.35 0.064
Statin on ICU day 1 0.35 0.09 - 1.32 (n = 116) 0.122 0.18 0.03- 1.13 0.068
Admitted with an infection 2.42 1.02 - 5.73 0.044 0.985
Admission lactate 1.06 0.86 - 1.32 (n = 110) 0.579 0.209
Admission white cell count 1.00 0.93 - 1.06 (n = 115) 0.880 0.570
Cardiovascular dysfunction 2.80 1.55 - 5.05 0.001 2.06 1.02 - 4.14 0.044
Renal dysfunction 2.21 1.10 - 4.45 0.026 2.32 0.93 - 5.79 0.070
Hepatic dysfunction 2.67 1.11 - 6.39 0.028 0.248
Haematological dysfunction 1.86 0.87 - 3.99 0.111 0.714
1OR (odds ratio) per one unit change, as appropriate for each variable. 2Value adjusted for other variables when OR and 95% CI (confidence interval) presented.
3Likelihood ratio value for variable selection when OR and 95% CI not presented. APACHE, acute physiology and chronic health evaluation; ICU, intensive care
unit; OPR, operating room; PaO2/FiO2,
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inflammatory response syndrome (SIRS) criteria were
also not associated with organ dysfunction.
Alberti et al sought risk factors for worsening sepsis in
infected ICU patients admitted to 28 international ICUs
[1]. The cumulative incidence of severe sepsis/septic
shock was 20% and 24% at days 10 and 30, respectively.
Interestingly, ICU mortality ranged from 10.1% in those
who did not develop severe sepsis to 95.7% in those
who remained in septic shock after 30 days.
Rangel-Fausto et al studied 2527 ICU and ward
patients with at least two SIRS criteria in a single North
American centre [2]. They provided the first evidence
that patients with SIRS progressed to sepsis, severe sepsis
and septic shock. While numerous infectious and non-
infectious illnesses can trigger a systemic inflammatory
response, the validity of SIRS criteria is being questioned
and available data do not support the use of SIRS criteria,
individually or collectively, as a predictive tool [17,19-23].
We recently reported risk factors for AOF in a single-
centre retrospective study in which 1397 mechanically
ventilated patients without non-respiratory organ failure
during the first 24 hours after ICU admission were fol-
lowed for up to 15 days after admission [24]. APACHE II
score and APACHE admission category (cardiovascular
and neurological) were strongly associated with AOF.
Our study differs from these studies in two ways. First,
we selected patients who, though less severely ill, were still
deemed sick enough to receive positive pressure respira-
tory support. We therefore included all at-risk patients.
We believe this to be a major limitation of other work in
this area: pre-selection eliminates many patient types and
makes it methodologically impossible to study the effect of
many predictor variables. For example, including only
patients with sepsis makes it challenging to evaluate the
effect of an infection on the risk of AOF given that, by
definition, all patients should have an infection.
Second, our study used more severe definitions for
AOF. Alberti et al defined organ dysfunction as a logistic
organ dysfunction score (LODS) > 1, while Dremsizov
and colleague used previously developed criteria which
loosely equates to a SOFA 1 to 2 (although the results
remained consistent when a sensitivity analysis using
stricter SOFA criteria were performed) [25,26]. The
implication is that patients we included with organ dys-
function (that is, with a SOFA 0, 1 to 2) would have been
excluded in the other studies, while we used stricter
Cumulative incidence of the primary outcome, as defined 
Cumulative incidence of new respiratory failure in 22 patients with 
respiratory SOFA <3 at inclusion 
Cumulative incidence of non-respiratory failure 
Figure 2 Cumulative incidence (CInc) of first episode of acute organ failure in any organ system. Day 1 is the first day of follow-up.
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definitions for our primary outcome variable. In effect,
we possibly enrolled patients who were already sicker
than the other studies, and studied their risk of progres-
sing to a very severe level of sickness.
Limitations
Our study has a number of limitations. First, the sample
size limited our ability to test multiple variables and
reduced the precision of the study estimates. Second,
the relatively small number of outcome events limited
our ability to control for other variables; study estimates
are therefore prone to residual confounding. For exam-
ple, while we believe the multinational recruitment to
be a strength, we were unable to assess the effect(s) of
clinical practice differences between the UK, Canadian
and Australian sites. Third, the short enrollment win-
dow at each site may have introduced a selection bias,
as the patients admitted during the period may not
reflect admissions during the rest of the year. Fourth,
the SOFA score categorizes continuous physiological
data; using these categories to determine the incidence
of a dichotomous outcome may mean that some
patients are already in ‘biological’ organ failure but have
not yet crossed the SOFA threshold. This is a limitation
inherent in all of the available scoring systems.
Conclusion
Based on these results, patients who receive positive pres-
sure respiratory support in the absence of non-respiratory
AOF are commonly admitted to ICU. This population
represent a plausible population for an interventional
study of organ protection. Acute organ failure is frequent
in these patients and these rates provide key control event
rate data. Organ failure developed within a short period
after admission but the data confirm the presence of a
treatment window. The presence of type 1 (oxygenation)
failure and cardiovascular dysfunction are risk factors to
consider when future trial selection criteria are designed.
Key messages
• To improve outcome, interventions aimed at pre-
venting acute organ failure in early critical illness
may be better than those used to treat established
organ failure
Figure 3 Cumulative incidence of the first episode of cardiovascular and renal failure. Day 0 is the day of screening and Day 1 the first
day of follow-up. Median time (in days) to acute organ failure is: cardiovascular (1.0), renal (2.0).
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• An at-risk population exists in ICU and this popu-
lation can be enrolled in future prevention trials.
• Baseline event rates are high, while a treatment
window between admission and the development of
non-respiratory organ failure appears to exist.
• This study provides crucial data necessary to
design future trials.
Additional material
Additional file 1: Table S1. Sequential Organ Failure Assessment (SOFA)
score. Describes the definitions used for selection criteria and outcome
measures. Table S2. Baseline data for all screened patients. Background
data of all screened patients, overall and by eligibility. Table S3.
Additional day of admission data for eligible patients. Additional
admission data, not included in main tables, for patients enrolled in the
study. Table S4. Evolution of organ function during follow-up. Evolution
of organ function, for individual organ systems, dichotomized by the
development of acute organ failure.
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